Five-Drug Antiemetic Combination for Cisplatin Chemotherapy

References

• Laszlo J, Lucas V S. Emesis as a critical problem in chemotherapy. N Engl J Med 1981; 305: 948–949
   PubMed Web of Science ®Google Scholar
• Whitehead V M. Cancer treatment needs better antiemetics. N Engl J Med 1975; 293: 199–200
   PubMed Web of Science ®Google Scholar
• Sridhar K S, Holland J F, Brown J C. Doxorubicin plus cisplatin in the treatment of Apudomas tumors. Cancer 1985; 55: 2634–2637
   PubMed Web of Science ®Google Scholar
• Jacobs A J, Deppe G, Cohen C J. A comparison of the antiemetic effects of droperidol and prochlorperazine in chemotherapy with cisplatinum. Gynecol Oncol 1980; 10: 55–57
   PubMed Web of Science ®Google Scholar
• Penta J, Poster D, Bruno S. The pharmacologic treatment of nausea and vomiting caused by cancer chemotherapy: A review. Antiemetics and Cancer Chemotherapy, J Laszlo. Williams and Wilkins, Baltimore 1983; 82–83
   Google Scholar
• Einhorn L H, Donohue J. CM-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1983; 87: 293–298, 1977
   Google Scholar
• Rozencweig M, Von Hoff D D, Slavik M, Muggia. Cis-diamminedichloroplatinum (II): A new anticancer drug. Ann Intern Med 1977; 86: 803–812
   PubMed Web of Science ®Google Scholar
• Sridhar K S, Donnelly E. Combination antiemetics for cisplatin chemotherapy. Cancer 1988; 61: 1508–1517
   PubMed Web of Science ®Google Scholar
• Peroutka S J, Snyder S H. Antiemetics. Neurotransmitter receptor binding predicts therapeutic actions. Lancet 1982; 1: 658–659
   PubMed Web of Science ®Google Scholar
• Sridhar K S, Varki J, Donnelly E. Toxicity of FED chemotherapy in non-small cell lung cancer. Am J Clin Oncol 1987; 10: 499–506
   PubMed Web of Science ®Google Scholar
• Sridhar K S, Ohiuma T, Biller H B. Combination chemotherapy with high dose methotrexate, bleomycin and cisplatin in management of head and neck squamous cell carcinoma. Am J Clin Oncol 1985; 8: 55–60
   PubMed Web of Science ®Google Scholar
• Sridhar K S, Thurer R, Kim Y. Multimodality treatment of non-small cell lung cancer: Response to cisplatin, VP-16, and 5-FU chemotherapy and to surgery and radiation therapy. J Surg Oncol 1988; 88: 193–215
   Google Scholar
• Sridhar K S. Allergic reaction to 5-fluorouracil infusion. Cancer 1986; 58: 862–864
   PubMed Web of Science ®Google Scholar
• Sridhar K S, Hirsch R, Fountzilas G. Sequential cfr-platin (DDP) and 5-fluorouracil (5-FU) in advanced squamous cell head and neck cancer (abstr). Proc Am Assoc Cancer Res 1985; 25: 180
   Web of Science ®Google Scholar
• Gralla R J, Itri L M, Pisko S E. Antiemetic efficacy of high dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905–909
   PubMed Web of Science ®Google Scholar
• Goslin R H, Gamick M B. Metoclopramide as an antiemetic in patients receiving cisplatin. The Treatment of Nausea and Vomiting Induced by Cancer Chemotherapy., DS Poster, JS Penta, S Brunos, New York 1981; 159–165
   Google Scholar
• Homesley H D, Gainey J M, Jobson V W. Double-blind placebo-controlled study of metoclopramide. N Engl J Med 1982; 307: 250, letter
   Google Scholar
• Strum S B, McDermed J E, Opfell R W. Intravenous metoclopramide: An effective antiemetic in cancer chemotherapy. J Am Med Assoc 1982; 247: 2683–2686
   PubMed Web of Science ®Google Scholar
• Daniels M, Belt R J. High dose metoclopramide as an antiemetic for patients receiving chemotherapy with cisplatinum. Oncol Nurs Forum 1982; 9: 20–22
   PubMedGoogle Scholar
• Schulze-Delrieu K. Metoclopromide. N Engl J Med 1981; 305: 28–33
   PubMedGoogle Scholar
• Parikh P M, Charak B S, Banavali S D. A prospective, randomized double-blind trial comparing metoclopramide alone with metoclopramide plus dexamethasone in preventing emesis induced by high-dose cisplatin. Cancer 1988; 62: 2263–2266
   PubMed Web of Science ®Google Scholar
• Bui N B, Marit G, Hoerni B. High-dose metoclopramide in cancer chemotherapy-induced nausea and vomiting. Cancer Treatment Rep 1982; 66: 2107–2108
   PubMedGoogle Scholar
• Kahn T, Elias E G, Mason G R. A single dose of metoclopramide in the control of vomiting from cw-dic Worodiammineplatinum (II) in man. Cancer Treat Rep 1978; 62: 1106–1107
   PubMedGoogle Scholar
• Carr B I, Doroshow J H, Morgan R J. Combination antiemetic therapy based on high doses of either prochlorperazine or metoclopramide give complete protection against platinum-induced emesis (abstr). Proc Am Soc Clin Oncol 1989; 18: 325
   Google Scholar
• Clark R A, Gralla R J, Kris M G. Exploring very high doses of metoclopramide (4–6 mg/kg): Preservation of efficacy and safety with only a single dose in a combination antiemetic regimen (abstr). Proc Am Soc Clin Oncol 1989; 8: 330
   Google Scholar
• Gomez E, Erazo A, Cervantes G. Comparison between metoclopramide, dexamethasone, diphenhydramine and diazepam (MDDD), and haloperidol, dexamethasone, diphenhydramine and diazepam (HDDD) antiemetic regimens in cisplatin-induced emesis (abstr). Proc Am Soc Clin Oncol 1989; 8: 333
   Google Scholar
• Rosenblatt E, Lev L M, Robinson E. High-dose dexamethasone and high-dose metoclopramide versus high-dose dexamethasone and sulpiride in the management of cisplatin-induced emesis. Oncology 1988; 45: 297–299
   PubMed Web of Science ®Google Scholar
• Kris M G, Tyson L B, Gralla R J. Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 1983; 309: 433
   PubMed Web of Science ®Google Scholar
• Seigel L J, Longo D L. The control of chemotherapy induced emesis. Ann Intern Med 1981; 95: 352–359
   PubMed Web of Science ®Google Scholar
• Cassileth P A, Lusk E J, Torri S. Antiemetic efficacy of dexamethasone in patients receiving cancer chemotherapy. Arch Intern Med 1983; 143: 1347–1349
   PubMed Web of Science ®Google Scholar
• Aapro M S, Plexia P M, Alberts D S. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 1984; 2: 466–471
   PubMed Web of Science ®Google Scholar
• Markman M, Sheidler V, Ettinger D S. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med 1984; 311: 549–552
   PubMed Web of Science ®Google Scholar
• Aapro M S, Alberts D S. High dose dexamethasone for prevention of cisplatin induced vomiting. Cancer Chemother Pharmacol 1981; 7: 11–14
   PubMed Web of Science ®Google Scholar
• Aapro M S, Alberts D S. High dose dexamethasone as an antiemetic in patients treated with cisplatin. N Engl J Med 1981; 305: 520
   PubMed Web of Science ®Google Scholar
• Drapkin R L, McAIanson E, Sokol G H. The antiemetic effect of dexamethasone in patients receiving cis-platinum (abstr). Proc Am Soc Clin Oncol 1981; 22: 340
   Google Scholar
• Bruera E D, Roca E, Cedaro L, Chacon R, Estevez R. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep 1983; 67: 381–383
   PubMedGoogle Scholar
• Gagen M, Gochnour D, Young D. A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy-induced vomiting. J Clin Oncol 1984; 2: 696–701
   PubMed Web of Science ®Google Scholar
• Donowitz G S, O'Quinn A G, Smith M L. Antiemetic efficacy of high dose corticosteroids and droperidol in cisplatin emesis. Gynecol Oncol 1984; 18: 320–325
   PubMed Web of Science ®Google Scholar
• Krebs H-B, Myers M B, Wheelcock J B. Combination antiemetic therapy in cisplatin-induced nausea and vomiting. Cancer 1985; 55: 2645–2648
   PubMed Web of Science ®Google Scholar
• Strum S B, McDermed J E, Liponi D F. High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: A single-blind crossover comparison of antiemetic efficacy. J Clin Oncol 1985; 3: 245–251
   PubMed Web of Science ®Google Scholar
• Senn H I, Glaus A, Bachmann-Mettler I. Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide. J Clin Oncol 1984; 2: 320–322
   PubMed Web of Science ®Google Scholar
• Mason B A, Dambra J, Grossman B. Effective control of cisplatin-induced nausea using high dose steroids and droperidol. Cancer Treat Rep 1982; 66: 243–245
   PubMedGoogle Scholar
• Kris M G, Gralla R J, Clark R A. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 1985; 69: 1257–1262
   PubMedGoogle Scholar
• Rosell R, Abad-Esteve A, Ribas-Mundo M. Evaluation of a combination antiemetic regimen including IV high-dose metoclopramide, dexamethasone, and diphenhydramine in cisplatin-based chemotherapy regimens. Cancer Treat Rep 1985; 69: 909–910
   PubMedGoogle Scholar
• Plezia P M, Alberts D S, Kessler J. Immediate termination of intractable vomiting induced by cisplatin combination chemotherapy using an intensive five-drug antiemetic regimen. Cancer Treat Rep 1984; 68: 1493–1495
   PubMedGoogle Scholar
• Kris M G, Gralla R J, Tyson L B. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Cancer 1985; 55: 527–534
   PubMed Web of Science ®Google Scholar
• Al-Idrissi H Y, Ibrahim E M, Abdullah K A. Antiemetic efficacy of high-dose dexamethasone: Randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine. Br J Cancer 1988; 57: 308–312
   PubMed Web of Science ®Google Scholar
• Kris M G, Gralla R J, Clark R A. Antiemetic control and prevention of side-effects of anticancer therapy with lorazepam and diphenhydramine when used in combination with metoclopramide plus dexamethasone: A double blind, randomized trial. Cancer 1987; 60: 2816–2822
   PubMed Web of Science ®Google Scholar
• Zaglama N E, Rosenblum S L, Sariano G P. Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy. Oncology 1986; 43: 27–32
   PubMed Web of Science ®Google Scholar
• Goldstein D, Levi J A, Woods R L, Russell. Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as antiemetics for cancer chemotherapy. Oncology 1989; 46: 105–108
   PubMed Web of Science ®Google Scholar
• Giaccone G, Bertetto O, Secat M A. High doses of methylpred-nisolone with or without alizapride in the prevention of cisplatin-induced emesis. A randomized, double-blind, crossover study. Oncology 1988; 45: 74–78
   PubMed Web of Science ®Google Scholar
• Grunbeg S M, Ehler E, McDermed J E. Oral metoclopramide with or without diphenhydramine: Potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst 1988; 80: 864–868
   PubMed Web of Science ®Google Scholar
• Citron M L, Johnston-Early A, Boyer M W. Droperidol (DP): Optimal dose and time of initiation (abstr). Proc Am Soc Clin Oncol 1984; 3: 106
   Google Scholar
• Grossman B, Lessin L S, Cohen P. Droperidol prevents nausea and vomiting from cis-platinum. N Engl J Med 1979; 301: 47
   PubMed Web of Science ®Google Scholar
• Lam H C, Cox F M. Clinical use of droperidol in patients with chemotherapy induced nausea and vomiting. Oncol Nurs Forum 1982; 9: 23–23
   PubMedGoogle Scholar
• Kelley S L, Braun T J, Meyer T J. Trial of droperidol as an antiemetic in cisplatin chemotherpy. Cancer Treat Rep 1986; 70: 469–472
   PubMedGoogle Scholar
• Morrow G R. Chemotherapy-related nausea and vomiting: Etiology and Management. Cancer J Physicians 1989; 39: 89–104
   PubMed Web of Science ®Google Scholar
• Laszlo J, Clark R A, Hanson D C. Lorazepam in cancer patients treated with cisplatin. A drug having antiemetic amnesia and anxiolytic effects. J Clin Oncol 1985; 3: 864–869
   PubMed Web of Science ®Google Scholar
• Bishop J F, Olver I N, Wolf M W. Lorazepam: A randomized, double-blind crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochloroperazine. J Clin Oncol 1984; 2: 691–695
   PubMed Web of Science ®Google Scholar
• Gordon C J, Pazdur R, Ziccarelli A. Metoclopramide versus metoclopramide and lorazepam. Superiority of combined therapy in the control of cisplatin-induced emesis. Cancer 1989; 63: 578–582
   PubMed Web of Science ®Google Scholar
• Bishop J F, Wolf M, Matthews J P. Randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy. Cancer Treat Rep 1987; 71: 1007–1011
   PubMedGoogle Scholar
• Bauer J, Perey L, Douglas P. Is sublingual lorazepam beneficial for patients on emetogenic chemotherapy? A double-blind randomized and cross-over study (abstr). Proc Am Soc Clin Oncol 1989; 8: 335
   Google Scholar
• Kris M G, Gralla R J, Tyson R A. Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metaclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108–114
   PubMed Web of Science ®Google Scholar
• Chabner B A, Myers C E. Clinical pharmacology of cancer chemotherapy. Cancer: Principles and Practice of Oncology, VT DeVita, Jr, S. Hellman, SA Rosenberg. J. B. Lip-pincott Co., Philadelphia 1989; 374–373
   Google Scholar
• Roila F, Tnato M, Basurto C. Protection from nausea and vomiting and persistence of antiemetic activity in cisplatin treated patients (pts). A randomized double-blind trial of the Italian Oncology Group for Clinical Research (GOIRC) (abstr). Proc Am Soc Clin Oncol 1989; 8: 329
   Google Scholar
• Longo D L, Wesley M, Howser D. Results of a randomized double blind cross over trial of scopolamine versus placebo administered transdermal patch for the control of cisplatin induced emesis. Cancer Treat Rep 1982; 66: 1975–1976
   PubMedGoogle Scholar
• Ungerleider J T, Adrysiak T, Fairbanks L. Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. Cancer 1982; 50: 636–645
   PubMed Web of Science ®Google Scholar
• Frytak S, Moertal C G, O'Fallon J R. Delta-9-tetrahydro-cannabinoid as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochloroperazine and a placebo. Ann Intern Med 1974; 91: 825–830
   Google Scholar
• Carey M P, Burish T G, Brenner D E. Delta-9-tetrahydrocannabinol in cancer chemotherapy: Research problems and issues. Ann Intern Med 1983; 99: 106–114
   PubMed Web of Science ®Google Scholar
• Einhorn L. Nabilone: An effective antiemetic agent in patients receiving cancer chemotherapy. Cancer Treat Rep 1982; 9: 55–61, suppl
   Google Scholar
• Sallan S E, Cronin C, Zelen M. Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980; 302: 135–138
   PubMed Web of Science ®Google Scholar
• Bindi M, Pepi F, Sebaste L. Combination of glucagon and low-dose metoclopramide in management of cisplatin-induced nausea and vomiting. J Natl Cancer Inst 1988; 80: 973
   PubMed Web of Science ®Google Scholar
• Grunberg S M, Stevenson L L, Russel C A. Dose ranging phase I study of the serotonin antagonist GR 38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989; 7: 1137–1141
   PubMed Web of Science ®Google Scholar
• Hesketh P J, Murphy W K, Leter E P. GR 38032F (GR-C507/75): A novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 1989; 7: 700–705
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Omura G A, Khojasteh A. GR 38032F: A new antiemetic effective in a multiple day regimen of cisplatin (DDP) chemotherapy (abstr). Proc Am Soc Clin Oncol 1989; 8: 328
   Google Scholar
• Leibunadgut U, Lancranjan I. First results with ICS 205–930 (5-HT₃) receptor antagonist in prevention of chemotherapy-induced emesis 1987; 1: 1198
   Google Scholar
• Carmichael J, Cantwell B MJ, Edwards C M. The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin. Br Med J 1988; 297: 110–111
   PubMed Web of Science ®Google Scholar
• Smaldone L, Fairchild C, Rozencweig M. Dose-range evaluation of BMY-25801, a non-dopaminergic antiemetic (abstr). Proc Am Soc Clin Oncol 1988; 7: 280
   Google Scholar
• Roila F, Tonato M, Cognetti F. Prevention of cisplatin-induced emesis: A double-blind multicenter crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675–678
   PubMed Web of Science ®Google Scholar